PL3362056T3 - Związki aminotioestrowe lub ich farmaceutycznie dopuszczalne sole do stosowania w leczeniu nowotworu - Google Patents

Związki aminotioestrowe lub ich farmaceutycznie dopuszczalne sole do stosowania w leczeniu nowotworu

Info

Publication number
PL3362056T3
PL3362056T3 PL16784831T PL16784831T PL3362056T3 PL 3362056 T3 PL3362056 T3 PL 3362056T3 PL 16784831 T PL16784831 T PL 16784831T PL 16784831 T PL16784831 T PL 16784831T PL 3362056 T3 PL3362056 T3 PL 3362056T3
Authority
PL
Poland
Prior art keywords
aminotioester
cancer
compounds
treatment
acceptable salts
Prior art date
Application number
PL16784831T
Other languages
English (en)
Inventor
Ismail Ceylan
Gerry QUASH
Mileidys PEREZ-ALEA
Guillaume Martin
Original Assignee
Advanced Biodesign
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biodesign filed Critical Advanced Biodesign
Publication of PL3362056T3 publication Critical patent/PL3362056T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
PL16784831T 2015-10-15 2016-10-14 Związki aminotioestrowe lub ich farmaceutycznie dopuszczalne sole do stosowania w leczeniu nowotworu PL3362056T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306649 2015-10-15
EP16784831.6A EP3362056B1 (en) 2015-10-15 2016-10-14 Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
PCT/EP2016/074697 WO2017064247A1 (en) 2015-10-15 2016-10-14 Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
PL3362056T3 true PL3362056T3 (pl) 2021-09-27

Family

ID=54360385

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16784831T PL3362056T3 (pl) 2015-10-15 2016-10-14 Związki aminotioestrowe lub ich farmaceutycznie dopuszczalne sole do stosowania w leczeniu nowotworu

Country Status (21)

Country Link
US (2) US20180296548A1 (pl)
EP (1) EP3362056B1 (pl)
JP (1) JP7062593B2 (pl)
CN (1) CN108348485A (pl)
AR (1) AR106352A1 (pl)
CA (1) CA3001204C (pl)
CY (1) CY1123950T1 (pl)
DK (1) DK3362056T3 (pl)
ES (1) ES2867965T3 (pl)
HR (1) HRP20210359T1 (pl)
HU (1) HUE053725T2 (pl)
IL (1) IL258610B (pl)
LT (1) LT3362056T (pl)
MX (1) MX381721B (pl)
PL (1) PL3362056T3 (pl)
PT (1) PT3362056T (pl)
RS (1) RS61630B1 (pl)
SI (1) SI3362056T1 (pl)
SM (1) SMT202100271T1 (pl)
WO (1) WO2017064247A1 (pl)
ZA (1) ZA201802399B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102941434B1 (ko) * 2019-07-31 2026-03-19 어드방스드 비오디자인 아미노티올에스터 화합물 및 이의 용도
EP4035666A1 (en) * 2021-01-29 2022-08-03 Advanced Biodesign Aminothiolester compound or derivative thereof for use as an immunomodulatory agent
WO2025229179A1 (en) * 2024-05-03 2025-11-06 Advanced Biodesign Use of aminothiolester compounds in combination with hypomethylating agents (hma) for the prevention and treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011059D0 (en) * 2000-05-08 2000-06-28 Pharmacia & Upjohn Spa Use of substituted acryloyl distamycin derivatives in the treatment of tumours associated with high levels of glutathione
FR2809727B1 (fr) 2000-05-31 2002-07-26 Galderma Res & Dev Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CA2842228A1 (en) * 2011-07-15 2013-01-24 University Health Network Combination treatment for cancer
CA2866080C (en) 2012-03-01 2021-01-19 University Of Cincinnati Ros-activated compounds as selective anti-cancer therapeutics

Also Published As

Publication number Publication date
SI3362056T1 (sl) 2021-05-31
PT3362056T (pt) 2021-04-22
ES2867965T3 (es) 2021-10-21
BR112018007310A2 (en) 2018-10-23
JP7062593B2 (ja) 2022-05-06
CN108348485A (zh) 2018-07-31
EP3362056A1 (en) 2018-08-22
IL258610B (en) 2021-04-29
HUE053725T2 (hu) 2021-07-28
CA3001204A1 (en) 2017-04-20
DK3362056T3 (da) 2021-03-29
CY1123950T1 (el) 2022-05-27
AR106352A1 (es) 2018-01-03
IL258610A (en) 2018-06-28
CA3001204C (en) 2023-08-29
HRP20210359T1 (hr) 2021-04-16
RS61630B1 (sr) 2021-04-29
MX2018004380A (es) 2018-05-11
ZA201802399B (en) 2020-01-29
WO2017064247A1 (en) 2017-04-20
SMT202100271T1 (it) 2021-07-12
US20180296548A1 (en) 2018-10-18
LT3362056T (lt) 2021-05-10
JP2018536699A (ja) 2018-12-13
US20230149378A1 (en) 2023-05-18
MX381721B (es) 2025-03-13
EP3362056B1 (en) 2021-02-24
HK1251476A1 (en) 2019-02-01

Similar Documents

Publication Publication Date Title
IL280899A (en) Heterocyclic compounds for cancer imaging and treatment and methods for their use
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
DK3431105T3 (da) Medicinsk sammensætning til behandling af cancer
IL256166B (en) Compounds for use in treating neuromuscular disorders
IL253945A0 (en) kdm1a inhibitors to treat the disease
HUE059694T2 (hu) Készítmény rák kezelésére
IL284875A (en) Lasofoxifene treatment of breast cancer
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
IL258953A (en) Dihydroimidazopyrazinone derivatives are useful for the treatment of cancer
KR20180084772A (ko) 암 치료를 위한 조합 치료법
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
IL259569A (en) Salts of conjugates for cancer therapy
IL265751B (en) Immunogenic compounds for cancer therapy
DK3532067T3 (da) Liposomal formulering til anvendelse til behandling af cancer
IL257355B (en) Selection of patients for combination therapy
HUE054998T2 (hu) Kombinációs terápiák emlõrák kezelésében való alkalmazásra
HUE053927T2 (hu) Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
IL258610B (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
IL261340B1 (en) Method and composition for treating cancer or skin lesion using a vaccine
HUE046209T2 (hu) Kompozíció porckoronggal összefüggõ fájdalom kezelésében történõ alkalmazásra
IL253933A0 (en) History of pyrimidine use in the treatment of cancer
PL3377061T3 (pl) Mirabegron do leczenia chorób siatkówki
PL3290051T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi